Quest Diagnostics (DGX) Net Income towards Common Stockholders (2009 - 2026)

Quest Diagnostics has reported Net Income towards Common Stockholders for 14 years, with the latest figure at $324.0 million in Q2 2026.

• Quarterly Net Income towards Common Stockholders rose 12.89% year-over-year to $324.0 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $1.1 billion (up 12.22% YoY) and the FY2025 annual result came in at $1.0 billion, up 11.31% from the prior year.
• Net Income towards Common Stockholders climbed to $324.0 million in Q2 2026 per DGX's latest filing, from $260.0 million in the prior quarter.
• Over five years, Net Income towards Common Stockholders peaked at $342.0 million in Q1 2022 and troughed at $113.0 million in Q4 2022.
• A 5-year average of $241.3 million and a median of $241.0 million in 2023 frame the typical range for Net Income towards Common Stockholders.
• The sharpest annual moves came in 2022 and 2023: Net Income towards Common Stockholders slumped 70.88% in 2022, then surged 74.34% in 2023.
• Over 5 years, Net Income towards Common Stockholders stood at $113.0 million in 2022, then soared by 74.34% to $197.0 million in 2023, then climbed by 17.26% to $231.0 million in 2024, then advanced by 7.79% to $249.0 million in 2025, then soared by 30.12% to $324.0 million in 2026.
• According to Business Quant data, Net Income towards Common Stockholders over the past three periods registered $324.0 million, $260.0 million, and $249.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.